PUBLISHER: Grand View Research | PRODUCT CODE: 2151783
PUBLISHER: Grand View Research | PRODUCT CODE: 2151783
The global radiopharmaceutical CRO market size was valued at USD 1.5 billion in 2025 and is projected to grow from USD 1.7 billion in 2026 to USD 3.9 billion by 2033, at a CAGR of 12.7% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 46.0% in 2025. The market growth is driven by the expanding radioligand therapy pipeline, increasing adoption of targeted radiopharmaceuticals in oncology, and rising complexity of radiopharmaceutical clinical trials.
The growing demand for specialized imaging and dosimetry services, and increasing outsourcing of discovery, preclinical, clinical, analytical, regulatory, and logistics activities to specialized CROs are expected to further fuel the growth of the radiopharmaceutical CRO industry. The short half-lives of radioisotopes, specialized site and facility requirements, radiation safety considerations, and stringent regulatory requirements further increase the need for experienced service providers. The expansion of radiopharmaceutical development across oncology, neurology, and cardiology is expected to support demand for specialized CRO capabilities over the coming years.
Global Radiopharmaceutical CRO Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global radiopharmaceutical CRO market report based on service, radiopharmaceutical type, radionuclide, development stage, application, end user, and region: